Eye Affecting Patents (Class 514/20.8)
-
Publication number: 20140050739Abstract: The present invention features the local administration of complement inhibitors for treatment of complement-mediated disorders. In certain embodiments the invention features inhibiting activation of one or more locally produced complement proteins. The invention provides sustained release formulations and devices comprising a complement inhibitor and methods of use thereof.Type: ApplicationFiled: October 11, 2013Publication date: February 20, 2014Applicant: Apellis Pharmaceuticals, Inc.Inventors: Cedric Francois, Pascal Deschatelets, Paul Olson
-
Patent number: 8653036Abstract: The present invention relates to methods of treating retinitis pigmentosa using ?-turn peptidomimetic cyclic compounds or derivatives thereof. The ?-turn peptidomimetic cyclic compounds can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs useful in treating retinitis pigmentosa.Type: GrantFiled: February 26, 2010Date of Patent: February 18, 2014Assignee: Mimetogen Pharmaceuticals Inc.Inventors: Garth Cumberlidge, Horacio U. Saragovi, Karen Meerovitch
-
Patent number: 8653032Abstract: Disclosed is a pharmaceutical composition for preventing or treating TRPV1 activity-related or inflammation-related, diseases or conditions, containing a Maillard peptide separated from well-aged traditional soy sauce as an active ingredient. The Maillard peptide in the present invention functions both as a TRPV1 agonist and a TRPV1 antagonist, and further functions as a TRPV1 activity modulator. Therefore, the Maillard peptide can be used for preventing or treating TRPV1 activity-related diseases such as pain, neurological diseases, urgent defecation, inflammatory bowel disease, respiratory diseases, urinary incontinence, overactive bladder, neurogenic / allergic / inflammatory skin diseases, skin, eye or mucosal irritation, hyperacusis, tinnitus, vestibular hypersensitivity, heart disease, etc.Type: GrantFiled: November 8, 2010Date of Patent: February 18, 2014Assignees: Korea Food Research Institute, SNU R & DB FoundationInventors: Mee-Ra Rhyu, Ah-Young Song, Eun-Young Kim, Seog Bae Oh, YoungJoo Lee, Won Chung Lim
-
Publication number: 20140044689Abstract: The disclosure generally describes methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject, such as diabetic retinopathy, cataracts, retinitis pigmentosa, glaucoma, macular degeneration, choroidal neovascularization, retinal degeneration, and oxygen-induced retinopathy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.Type: ApplicationFiled: May 17, 2013Publication date: February 13, 2014Inventors: Liping LIU, Shibo TANG, Xiaoling LIANG
-
Publication number: 20140045773Abstract: Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.Type: ApplicationFiled: September 11, 2013Publication date: February 13, 2014Applicant: Allergan, Inc.Inventors: Joseph G. Vehige, Peter A. Simmons, Joan-En Chang-Lin
-
Publication number: 20140038880Abstract: Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject.Type: ApplicationFiled: March 15, 2013Publication date: February 6, 2014Inventor: Gautam Ghatnekar
-
Patent number: 8642066Abstract: Disclosed is a drug delivery system for delivering a drug at a sustained constant rate for a long period, which can be transplanted into an affected part safely and in a simple manner and can deliver a drug to the affected part for a long period. Specifically disclosed is a sustained drug delivery system in which an implant is implanted into a body, wherein the implant is a PEG capsule comprising a box-shaped PEG and a porous PEG sheet.Type: GrantFiled: February 16, 2012Date of Patent: February 4, 2014Assignee: Tohoku UniversityInventors: Toshiaki Abe, Nobuhiro Nagai, Hirokazu Kaji, Takeaki Kawashima, Matsuhiko Nishizawa, Koji Nishida
-
COMPOSITION AND METHOD FOR REDUCING TISSUE DAMAGE FROM INFLAMMATORY DISORDER OR PATHOGENIC INFECTION
Publication number: 20140030251Abstract: Compositions and methods for preventing or ameliorating tissue damage caused by an inflammatory disorder or pathogenic infections are described. In one aspect, a method for preventing or ameliorating tissue damage caused by an inflammatory disorder or pathogenic infection comprises administering to a subject a therapeutically effective amount of a neuregulin. In another aspect, the composition comprises one or more active agents that: (a) increase expression or activity of a neuregulin; (b) inhibit the expression or activity of CXCL10, STAT3 or HEME; or (c) both (a) and (b).Type: ApplicationFiled: July 24, 2012Publication date: January 30, 2014Applicant: MOREHOUSE SCHOOL OF MEDICINEInventors: Byron D. Ford, Jonathan Stiles, Gregory Ford -
Publication number: 20140018306Abstract: The present invention relates to identification of a human gene, Complement Factor H (CFH), associated with the occurrence for developing age related macular degeneration (AMD), which is useful for identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis of AMD.Type: ApplicationFiled: September 26, 2013Publication date: January 16, 2014Applicants: The Rockefeller University, Yale UniversityInventors: Josephine Hoh, Robert J. Klein
-
Publication number: 20140018305Abstract: Provided herein are compositions and methods for use in treating or preventing macular degeneration in a subject.Type: ApplicationFiled: July 5, 2013Publication date: January 16, 2014Inventors: Baerbel ROHRER, Robert GOURDIE, Gautam GHATNEKAR
-
Publication number: 20140018296Abstract: The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a low density lipoprotein receptor (LDLR) or LDLR family member. Therapeutic uses for the conjugates are also provided.Type: ApplicationFiled: September 23, 2013Publication date: January 16, 2014Applicant: Alcon Research, Ltd.Inventor: Jon E. Chatterton
-
Publication number: 20140005125Abstract: New designed ankyrin repeat proteins with binding specificity for PDGF-BB are described, as well as nucleic acids encoding such PDGF binding proteins, pharmaceutical compositions comprising such proteins and the use of such proteins in the treatment of diseases.Type: ApplicationFiled: June 27, 2013Publication date: January 2, 2014Inventor: Michael BAUMANN
-
Patent number: 8618045Abstract: Provided is a modified human tumor necrosis factor receptor-1 polypeptide or a fragment thereof that binds to a tumor necrosis factor in vivo or ex vivo. The modified human tumor necrosis factor receptor-1 polypeptide or fragment exhibits improved ability to bind tumor necrosis factor and resistance to proteases.Type: GrantFiled: December 21, 2011Date of Patent: December 31, 2013Assignee: Hanall Biopharma Co., Ltd.Inventors: Sung Wuk Kim, Sung Soo Jun, Seung Kook Park, Song Young Kim, Eun Sun Kim, Jae Kap Jeong, Ha Na Kim, Yeon Jung Song
-
Patent number: 8618064Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.Type: GrantFiled: August 28, 2007Date of Patent: December 31, 2013Assignee: Allergan, Inc.Inventors: Andrew Acheampong, Diane Tang-Liu, James N. Chang, David F. Power
-
Publication number: 20130345150Abstract: An ophthalmic composition comprising a polyaphron dispersion.Type: ApplicationFiled: March 14, 2012Publication date: December 26, 2013Inventor: Fraser Steele
-
Patent number: 8613929Abstract: The present invention relates to nucleic acids and polypeptides encoded thereby, whose expression is modulated in brain microvascular endothelial cells undergoing early dynamic inflammation-induced changes in blood-brain bather functionality. Such polypeptides are referred to as lipopolysaccharide-sensitive (LPSS) polypeptides. These nucleic acids and polypeptides may be useful in methods for controlling blood-brain bather properties in mammals in need of such biological effects. This includes the diagnosis and treatment of disturbances in the blood-brain/retina barrier, brain (including the eye) disorders, as well as peripheral vascular disorders. Additionally, the invention relates to the use of anti-LPSS polypeptide antibodies or ligands as diagnostic probes, as blood-brain barrier targeting agents or as therapeutic agents as well as the use of ligands or modulators of expression, activation or bioactivity of LPSS polypeptides as diagnostic probes, therapeutic agents or drug delivery enhancers.Type: GrantFiled: July 21, 2011Date of Patent: December 24, 2013Assignee: TO-BBB Holding B.V.Inventors: Pieter J. Gaillard, Albertus G. De Boer, Arjen Brink
-
Publication number: 20130338058Abstract: In one embodiment, the invention provides a method of suppressing, inhibiting, preventing, or treating conjunctivitis in a subject, comprising the step of administering an effective amount of a lipid or phospholipid moiety bound via an ester or amide bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof to a subject with conjunctivitis.Type: ApplicationFiled: January 9, 2013Publication date: December 19, 2013Applicant: YISSUM RESEARCH DEVELOPMENT COMPANYInventor: YISSUM RESEARCH DEVELOPMENT COMPANY
-
Patent number: 8609613Abstract: The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.Type: GrantFiled: July 18, 2012Date of Patent: December 17, 2013Assignee: Bristol-Myers Squibb CompanyInventors: Yan Chen, Elena Getmanova, Martin C. Wright, Alan S. Harris, Ai Ching Lim, Jochem Gokemeijer, Lin Sun, Michael Wittekind
-
Publication number: 20130324458Abstract: The present invention is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The Klotho fusion polypeptides of the invention include at least a Klotho protein or an active fragment thereof. In one embodiment, the fusion polypeptide comprises a Klotho polypeptide, a FGF (such as FGF23) and (optionally) a modified Fc fragment. The Fc fragment can, for example, have decreased binding to Fc-gamma-receptor and increased serum half-life. The Klotho fusion proteins are useful in the treatment and prevention of a variety of age-related conditions and metabolic disorders. In another embodiment, the fusion polypeptide comprises a FGF (such as FGF23) and a modified Fc fragment.Type: ApplicationFiled: May 29, 2013Publication date: December 5, 2013Inventors: David GLASS, Shou-Ih HU
-
Publication number: 20130316942Abstract: The present invention relates to potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties. Specifically, the present invention relates to short peptides having these properties, and to methods and uses of such short peptides in clinical and cosmetic applications.Type: ApplicationFiled: August 9, 2013Publication date: November 28, 2013Inventors: Josef Mograbi, Daphne Atlas, Shoshana Keynan
-
Publication number: 20130310327Abstract: Histatins may be used for corneal wound healing and as a treatment for ocular surface disease in humans and other animals. For example, histatins could be included in eye drops, eye gels, ointment, glue, or embedded in (polymer) contact lenses.Type: ApplicationFiled: March 7, 2013Publication date: November 21, 2013Applicant: RAPID PATHOGEN SCREENING, INC.Inventors: Robert P. Sambursky, Robert W. VanDine, Peter Condon
-
Publication number: 20130310326Abstract: Histatins may be used for corneal wound healing and as a treatment for ocular surface disease in humans and other animals. For example, histatins could be included in eye drops, eye gels, ointment, glue, or embedded in (polymer) contact lenses.Type: ApplicationFiled: March 7, 2013Publication date: November 21, 2013Applicant: RAPID PATHOGEN SCREENING, INC.Inventors: Robert P. Sambursky, Robert W. VanDine, Peter Condon
-
Publication number: 20130296255Abstract: The invention relates to Factor H gene polymorphisms and haplotypes associated with an elevated or a reduced risk of AMD. The invention provides methods and reagents for diagnosis and treatment of AMD.Type: ApplicationFiled: July 17, 2013Publication date: November 7, 2013Inventor: Gregory S. Hageman
-
Publication number: 20130296254Abstract: The present invention features the use of compstatin and complement inhibiting analogs thereof for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, choroidal neovascularization, and/or retinal neovascularization. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a second therapeutic agent. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a gel-forming material, e.g., soluble collagen, and methods of administering the compositions.Type: ApplicationFiled: March 1, 2012Publication date: November 7, 2013Applicant: POTENTIA PHARMACEUTICALS, INC.Inventors: Pascal Deschatelets, Paul Olson, Cedric Francois
-
Publication number: 20130288964Abstract: The current invention relates to the use of a peptide comprising an amino acid sequence in the preparation of a medicament for the regeneration of tissue, preferably for the treatment of a wound. Further the invention relates to compositions comprising such peptides, and use of said peptides in both medical and nonmedical (cosmetic) applications.Type: ApplicationFiled: March 14, 2013Publication date: October 31, 2013Inventors: Johannes Gerhardus Maria Bolscher, Arie van Nieuw Amerongen, Engelmundus Cornelis Ignatius Veerman, Menno Johannes Oudhoff, Willem van't Hof, Kamran Nazmi, Petronella Adriana Maria van den Keijbus
-
Publication number: 20130288985Abstract: This application discloses pharmaceutical compositions (e.g., oral, parenteral or topical ophthalmic formulations) for treating Fuchs endothelial corneal dystrophy (FECD) with one or more Nrf2 activators and/or mitochondrially targeted antioxidants. The compositions may be topically administered to the eye and are effective in the treatment of FECD. The invention further provides methods of treating FECD by in a subject in need of such treatment by topical application of one or more Nrf2 activators and/or mitochondrially of the invention.Type: ApplicationFiled: June 30, 2011Publication date: October 31, 2013Applicant: The Schepens Eye Research Institute Inc.Inventor: Ula V. Jurkunas
-
Patent number: 8563026Abstract: Multilayer protein films are provided, which comprise native bacteriorhodopsin and/or specialized bacteriorhodopsin mutants as the photoactive element. Also provided are artificial subretinal and epiretinal implants carrying such bacteriorhodopsin films, as well as methods for making and using the same, for example, to treat retinal diseases and conditions.Type: GrantFiled: March 5, 2010Date of Patent: October 22, 2013Assignee: University of ConnecticutInventors: Robert R. Birge, Megan Nollenberger, Matthew Ranaghan, Daniel J. Sandberg, Nicole Wagner
-
Patent number: 8563520Abstract: The present invention relates to methods to treat glaucoma and glaucoma-related conditions through the regulation of changes in gene expression that are mediated by high intraocular pressure or ?2 macroglobulin administration. Glaucoma, retinal ganglion cell (RGC) death and chronic ocular hypertension are treated using pharmaceutical compositions which comprise substances that inhibit the expression or activity of intraocular pressure-regulated early genes (IPREGs) or their gene products that are up-regulated by high intraocular pressure or ?2 macroglobulin administration and/or which increase the expression or activity of IPREGs or their gene products that are down-regulated by high intraocular pressure or ?2 macroglobulin administration. The invention also relates to methods of identifying an IPREG and methods to test for chronic ocular degeneration and the onset of RGC stress in an individual by measuring the expression level of IPREG proteins.Type: GrantFiled: May 22, 2008Date of Patent: October 22, 2013Assignee: McGill UniversityInventor: H. Uri Saragovi
-
Publication number: 20130273065Abstract: The present invention comprises a composition with means to inhibit the function of the inflammatory cytokine IL-1 and methods for using this composition to treat inflammatory disease of ocular and adnexal tissues by topical administration. The present invention also discloses devices for delivering this composition to target tissues.Type: ApplicationFiled: March 12, 2013Publication date: October 17, 2013Inventors: Reza Dana, Mohammad Dastjerdi
-
Patent number: 8551487Abstract: Disclosed are methods and materials for inhibiting (e.g., treating or preventing) uveitis in a subject, including treatment refractory uveitis, using anti-IL-1? binding molecules (e.g., IL-1? binding antibodies or binding fragment thereof).Type: GrantFiled: May 6, 2011Date of Patent: October 8, 2013Assignee: Xoma Technology, Ltd.Inventors: Alan M. Solinger, Ahmet Gül
-
Patent number: 8551467Abstract: An ophthalmic composition, and methods of use thereof, including for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface or for the treatment or care of ophthalmic devices. The ophthalmic composition comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The ophthalmic composition may also comprise one or more ophthalmically acceptable agents.Type: GrantFiled: July 2, 2012Date of Patent: October 8, 2013Assignees: The Regents of the University of California, Schepens Eye Research InstituteInventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
-
Patent number: 8551952Abstract: Provided herein are methods for treatment of ocular diseases. The methods comprise administering a compound of general Formula (I): wherein R1, R2, R3, R4 and Ak are as defined in the specification.Type: GrantFiled: April 27, 2012Date of Patent: October 8, 2013Assignee: Scynexis, Inc.Inventor: David Renwick Houck
-
Publication number: 20130244927Abstract: The invention provides human signal peptide-containing proteins (HSPP) and polynucleotides which identify and encode HSPP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HSPP.Type: ApplicationFiled: February 15, 2012Publication date: September 19, 2013Inventors: Preeti Lal, Y. Tom Tang, Gina A. Gorgone, Neil C. Corley, Karl J. Guegler, Mariah R. Baughn, Ingrid E. Akerblom, Janice Au-Young, Henry Yue, Chandra Patterson, Roopa Reddy, Jennifer L. Hillman, Olga Bandman
-
Publication number: 20130237472Abstract: The present invention relates to a modified human tumor necrosis factor receptor-1 polypeptide which is capable of binding to a tumor necrosis factor in vivo or ex vivo, or to a fragment thereof.Type: ApplicationFiled: September 7, 2011Publication date: September 12, 2013Applicant: HANALL BIOPHARMA CO., LTD.Inventors: Sung Wuk Kim, Sung Soo Jun, Seung Kook Park, Song Young Kim, Eun Sun Kim, Jae Kap Jeong, Ha Na Kim, Yeon Jung Song
-
Patent number: 8529871Abstract: The invention is directed to a method for preventing nasolacrimal duct obstruction (NLDO) in a patient receiving high dose radioactive iodine for treatment of cancer. The method includes administering an effective amount of perchlorate anion to the eyes of the patient.Type: GrantFiled: February 4, 2008Date of Patent: September 10, 2013Inventor: Kenneth Eli Morgenstern
-
Patent number: 8524230Abstract: Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity.Type: GrantFiled: December 21, 2009Date of Patent: September 3, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Daniel J. Cua, Robert A. Kastelein, Van T. Tsai, Rachel Caspi, Phyllis Silver
-
Publication number: 20130225505Abstract: Disclosed herein is a method of treating neovascular diseases of the anterior segment of the human eye, the method comprising administering to the eye muteins of human tear lipocalin that target VEGF.Type: ApplicationFiled: November 19, 2012Publication date: August 29, 2013Applicant: ALLERGAN, INC.Inventor: ALLERGAN, INC.
-
Patent number: 8518412Abstract: The invention provides a polypeptide containing an amino acid sequence, which is a particular partial sequence of lacritin and is characterized by gyro-modification of N-terminal glutamine. The polypeptide promotes adhesion between a cell and extracellular matrix and is stable in aqueous solution.Type: GrantFiled: September 16, 2010Date of Patent: August 27, 2013Assignee: Senju Pharmaceutical Co, Ltd.Inventors: Takeshi Nakajima, Tomoko Nakajima, Mitsuyoshi Azuma
-
Publication number: 20130216539Abstract: The present invention includes methods of generating derivatives of a protein, as well as methods of treating a subject with the derivatized proteins. More particularly, the present invention includes methods of generating derivatives of HSP 70 proteins and methods of treating a subject with the derivatized HSP 70 proteins.Type: ApplicationFiled: February 15, 2013Publication date: August 22, 2013Applicant: ALS Biopharma, LLCInventor: ALS Biopharma, LLC
-
Publication number: 20130210747Abstract: Disclosed herein are novel methods and compositions for targeting drug delivery systems to specific cells. One aspect relates to a drug delivery system comprising an elastin-like peptide (ELP) component and a ligand selected from the group consisting of mIgA and knob capable of either drug encapsulation or drug attachment. Further aspects relate to drug delivery systems comprising an elastin-like peptide (ELP) component and a ligand; wherein the ligand specifically binds to a receptor selected from the group consisting of CAR and pIgR. Further aspects include the novel transcytosing properties of the elastin-like peptide and the ligand, knob. Also provided are methods and pharmaceutical compositions comprising the disclosed therapeutics.Type: ApplicationFiled: February 11, 2013Publication date: August 15, 2013Applicant: UNIVERSITY OF SOUTHERN CALIFORNIAInventor: University of Southem California
-
Patent number: 8506944Abstract: An ophthalmic composition, and methods of use thereof, including for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface or for the treatment or care of ophthalmic devices. The ophthalmic composition comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The ophthalmic composition may also comprise one or more ophthalmically acceptable agents.Type: GrantFiled: October 23, 2009Date of Patent: August 13, 2013Assignees: The Regents of the University of California, Schepens Eye Research InstituteInventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
-
Publication number: 20130203680Abstract: The present invention relates to methods of use of folate conjugates for treating inflammatory diseases of the eye, to folate conjugates for use in treating inflammatory diseases of the eye, and to folate conjugates for use in the manufacture of a medicament for treating inflammatory diseases of the eye. More particularly, the invention is directed to the use of folate linked to one or more anti-inflammatory agents for each of the above-described uses.Type: ApplicationFiled: September 21, 2011Publication date: August 8, 2013Applicant: ENDOCYTE, INC.Inventors: Christopher Paul Leamon, Iontcho Radoslavov Vlahov, Yingjuan June Lu
-
Patent number: 8501174Abstract: Therapeutic methods are disclosed herein.Type: GrantFiled: June 28, 2010Date of Patent: August 6, 2013Assignee: Allergan, Inc.Inventors: Gregg Feinerman, Neil Barth, Rhett M. Schiffman, Pamela S. Barnett
-
Publication number: 20130195868Abstract: Disclosed herein are methods for administering an IL-1 or IL-17 antagonist for treating ocular surface disorders, e.g., a dry eye disorder. The antagonists can be administered topically using an opthalmic composition.Type: ApplicationFiled: June 23, 2011Publication date: August 1, 2013Applicant: ELEVEN BIOTHERAPEUTICS, INC.Inventor: Burt A. Adelman
-
Publication number: 20130196926Abstract: Described herein are bioresponsive protein polymers for therapeutic applications, including delivery to physiologically demanding environments, such as the eye surface. Bioresponsive protein polymers can be fused with biopharmaceuticals using genetic engineering techniques for enhanced therapeutic activity. In certain embodiments, the unique temperature-sensitive phase separation properties of bioresponsive protein polymers, allows generation of therapeutics resistant to ocular clearance. Such fusion proteins containing bioresponsive protein polymers and biopharmaceuticals allow retention of drugs in the eye for much longer periods of time.Type: ApplicationFiled: July 26, 2012Publication date: August 1, 2013Applicant: UNIVERSITY OF SOUTHERN CALIFORNIAInventors: John Andrew MacKay, Wan Wang
-
Publication number: 20130189363Abstract: ?-Hairpin peptidomimetics of the general formula Cyclo (-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-Xaa14-), enantiomers and pharmaceutically acceptable salts thereof, with Xaa1-Xaa14 being amino acid residues of certain types which are defined in the description and the claims, have anti-infective activity, e.g. to selectively inhibit the growth of or to kill microorganisms such as Bacillus subtilis and/or Shigella boydii. They can be used as medicaments to treat or prevent infections or as disinfectants for foodstuffs, cosmetics, medicaments or other nutrient-containing materials. These peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.Type: ApplicationFiled: August 5, 2010Publication date: July 25, 2013Applicants: UNIVERSITÄT ZÜRICH, POLYPHOR AGInventors: Daniel Obrecht, Frank Otto Gombert, John Anthony Robinson, Krystyna Patora-Komisarska
-
Patent number: 8491905Abstract: Disclosed herein is a method of treating dry eye with a KLK-13 antibody.Type: GrantFiled: June 28, 2012Date of Patent: July 23, 2013Assignee: Allergan, Inc.Inventors: Michael E. Stern, Karyn F. Siemasko, Christopher Schaumburg, Jianping Gao
-
Patent number: 8491912Abstract: Disclosed herein TPV1 is a method of treating ocular and systemic conditions by administering IL-10 and TPV134R polypeptides.Type: GrantFiled: June 16, 2011Date of Patent: July 23, 2013Assignee: Allergan, Inc.Inventors: Michael E. Stern, Christopher S. Schaumburg, Karyn F. Siemasko, Larry A. Wheeler
-
Publication number: 20130178421Abstract: The invention provides a delivery system comprising a cell penetrating peptide, 10 histidines, and an interfering RNA molecule. The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided.Type: ApplicationFiled: December 6, 2012Publication date: July 11, 2013Applicant: ALCON RESEARCH, LTD.Inventor: ALCON RESEARCH, LTD.
-
Publication number: 20130177580Abstract: The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a transferrin receptor (TfR). Therapeutic uses for the conjugates are also provided.Type: ApplicationFiled: February 12, 2013Publication date: July 11, 2013Applicant: ALCON RESEARCH, LTD.Inventor: Alcon Research, Ltd.